Sutro Biopharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2022

Summary of Computation of Company's Basic and Diluted Net Loss Per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share.


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2022			2021			2022			2021
	(in thousands, except share and per share amounts)
Numerator:
Net loss	$	(19,488	)	$	(30,902	)	$	(84,610	)	$	(67,413	)
Denominator:
Shares used in computing net loss per share		52,345,732			46,162,544			48,622,258			46,060,010
Net loss per share, basic and diluted	$	(0.37	)	$	(0.67	)	$	(1.74	)	$	(1.46	)

Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share

The following common stock equivalents were excluded from the computation of diluted net loss per share for the period ended September 30, 2022 and 2021, because including them would have been antidilutive:


	As of September 30,
	2022		2021
Common stock options issued and outstanding		7,473,527		6,533,772
Restricted stock units issued and outstanding		3,893,070		2,262,776
Warrants to purchase common stock		127,616		153,070
Employee stock purchase plan		23,346		6,663
Total		11,517,559		8,956,281